In combination with three anti-cancer therapies, daratumumab (anti-CD38), alemtuzumab (anti-CD54), and obinutuzumab (anti-CD20), TRX-CD47 synergistically increases the phagocytic potential of macrophages and allows for more efficient elimination of malignant B cells (177). The gene discussed is CD47; the disease is cancer.